Conivaptan for the treatment of hyponatremia

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 3, 2010, Pages 343-352

  Zeltser, David ^a   Steinvil, Arie ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Arginine vasopressin; Conivaptan; Hyponatremia

Indexed keywords

AMLODIPINE; ARGIPRESSIN; CAPTOPRIL; CONIVAPTAN; DIGOXIN; FUROSEMIDE; KETOCONAZOLE; LIXIVAPTAN; MIDAZOLAM; PLACEBO; SAMCA; SATAVAPTAN; SIMVASTATIN; SPIRONOLACTONE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; WARFARIN;

ABSENCE OF SIDE EFFECTS; ANEMIA; AREA UNDER THE CURVE; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INSOMNIA; LIVER CIRRHOSIS; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHARMACODYNAMICS; PLASMA OSMOLALITY; PNEUMONIA; POLYURIA; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SORE THROAT; ST SEGMENT DEPRESSION; THIRST; THRUSH; URINARY TRACT INFECTION; VOMITING;

EID: 77952519857     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.16     Document Type: Review

References (55)

1. Flear C T, Gill GV, Burn J. Hyponatraemia: mechanisms and management. Lancet 2 (8236), 26-31 (1981).
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am. J. Med. 119 (7 Suppl. 1), S30-S35 (2006).
3. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med. 120 (11 Suppl. 1), S1-S21 (2007).
4. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin. Nephrol. 29 (3), 282-299 (2009).
5. Thurman J, Halterman R, Berl T. Therapy of dysnatremia disorders. In: Therapy in Nephrology and Hypertension. Brady H, Wilcox C (Eds). Saunders, London, UK, 335-348 (2003).
6. Adrogue HJ, Madias NE. Hyponatremia. N. Engl. J. Med. 342 (21), 1581-1589 (2000).
7. Mount DB. Hyponatremia: introduction. Semin. Nephrol. 29 (3), 175-177 (2009).
8. Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int. 76 (6), 587-589 (2009).
9. Miller M. Syndromes of excess antidiuretic hormone release. Crit. Care Clin. 17 (1), 11-23, v (2001).
10. Rossi NF, Cadnapaphornchai P. Disordered water metabolism: hyponatremia. Crit. Care Clin. 3 (4), 759-777 (1987).
11. Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. J. Am. Geriatr. Soc. 43 (12), 1410-1413 (1995).
12. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122 (9), 857-865 (2009).
13. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am. J. Med. 119 (7 Suppl. 1), S36-S42 (2006).
14. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol. Metab. Clin. North Am. 30 (3), 671-694, vii (2001).
15. Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 118 (4), 410-421 (2008).
16. Verbalis JG. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. 29 (1), 1-9 (2002).
17. Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol. Metab. Clin. North Am. 31 (1), 121-140 (2002).
18. Mount DB. The brain in hyponatremia: both culprit and victim. Semin. Nephrol. 29 (3), 196-215 (2009).
19. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med. 102 (2), 164-168 (1985).
20. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am. J. Med. 42 (5), 790-806 (1967).
21. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am. J. Physiol. 248 (3 Pt 2), H396- H402 (1985).
22. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve. Clin. J. Med. 73 (Suppl. 3), S24-S33 (2006).
23. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J. Pharmacol. Exp. Ther. 316 (2), 564-571 (2006).
24. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371 (9624), 1624-1632 (2008). Extensive review on this class of drugs.
25. Moen MD, Keating GM. Intravenous conivaptan. Am. J. Cardiovasc. Drugs 8 (5), 341-348; discussion 349 (2008). Alternate review on this class of drug.
26. Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J. Clin. Endocrinol. Metab. 82 (4), 1054-1057 (1997).
27. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 16 (4), 846-851 (2005).
28. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355 (20), 2099-2112 (2006).
29. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol. 47 (8), 1615-1621 (2006).
30. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37 (1), 182-191 (2003).
31. Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Soc. Nephrol. 1 (6), 1154-1160 (2006).
32. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V (2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48 (1), 204-213 (2008).
33. Okuno K, Taya K, Marmarou CR et al. The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. Acta Neurochirurgica 102, 431-436 (2008).
34. Taya K, Gulsen S, Okuno K, Prieto R, Marmarou CR, Marmarou A. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta neurochirurgica 102, 425-429 (2008).
35. Yamamura Y, Ogawa H, Chihara T et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252 (5005), 572-574 (1991).
36. Griebel G, Simiand J, Serradeil-Le Gal C et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl Acad. Sci. USA 99 (9), 6370-6375 (2002).
37. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170, 473-512 (2008).
38. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin. Chim. Acta 337 (1-2), 169-172 (2003).
39. Hoorn E, Lindemans J, Zietse R. Hyponatremia in hospitalized patients: epidemiology, etiology and symptomatology [abstract]. J. Am. Soc. Nephrol. 15561A (2004).
40. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am. J. Med. Sci. 337 (1), 28-36 (2009).
41. Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebocontrolled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 91 (6), 2145-2152 (2006).
42. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 69 (12), 2124-2130 (2006).
43. Tahara A, Tomura Y, Wada KI et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282 (1), 301-308 (1997).
44. Matsuhisa A, Kikuchi K, Sakamoto K, Yatsu T, Tanaka A. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-[5- (substituted methylidene) -2, 3, 4, 5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4-[5- (substituted methyl) -2, 3-dihydro-1H-1-benzoazepine-1- carbonyl] benzanilide derivatives. Chem. Pharm. Bull. 47 (3), 329-339 (1999).
45. Burnier M, Fricker AF, Hayoz D, Nussberger J, Brunner HR. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur. J. Clin. Pharmacol. 55 (9), 633-637 (1999). Among the first descriptions of the drug.
46. Weber R, Pechere-Bertschi A, Hayoz D et al. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension 30 (5), 1121-1127 (1997). Among the first descriptions of the drug.
47. Mao ZL, Stalker D, Keirns J. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V (1A)/V (2) -receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin. Ther. 31 (7), 1542-1550 (2009).
48. Verbalis J, Bisaha J, Smith N. Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J. Am. Soc. Nephrol. 15356A (abstract SA-P0254) (2004). First clinical trial.
49. Gross P, Bisaha J, Smith N. Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. J. Am. Soc. Nephrol. 15355A (abstract SA-P0243) (2004).
50. Ghali J, Smith N. Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia. J. Am. Soc. Nephrol. 15355A (abstract SA-P0251) (2004).
51. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 27 (5), 447-457 (2007). Important clinical trial leading to US FDA approval of conivaptan.
52. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin. Endocrinol. (Oxf.) 69 (1), 159-168 (2008).
53. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. DOI: 10.1093/ndt/gfp731 (2010) (Epub ahead of print).
54. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocritical Care 11 (1), 14-19 (2009).
55. Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V (1A) and V (2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (20), 2417-2423 (2001).